A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Alopecia Areata

In brief

The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last approximately 48 weeks, including screening.

Key facts

Study ID: NCT07533006
Run by: Eli Lilly and Company
People needed: 60
Starts: 2026-04-14
Expected to finish: 2027-10-01
Last updated by the study team: 2026-08-06

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have severe Alopecia Areata (AA) that meets all of the following criteria:
Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score
The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years
No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months
Agree not to use any AA treatments during the study

You may not qualify if…

Primarily "diffuse" type of AA (characterized by diffuse hair shedding)
Are currently experiencing other forms of alopecia
Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study
Have received oral JAK Inhibitors in the past
Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study
Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness

Where it is running

Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue — San Antonio, Texas, United States (enrolling)
Jordan Valley Dermatology & Research Center — South Jordan, Utah, United States (enrolling)
Centrum Badan Klinicznych PI-House sp. z o.o. — Gdansk, Poland (enrolling)
Diamond Clinic — Krakow, Poland (enrolling)
Dermedic Jacek Zdybski — Ostrowiec Świętokrzyski, Poland (enrolling)
Centrum Medyczne Ginemedica — Wroclaw, Poland (enrolling)
Kelowna Health and Memory Centre — Kelowna, Canada (enrolling)
Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway — Santa Clarita, California, United States (enrolling)
Dar Clinical Research - Ottawa - Hunt Club Road — Ottawa, Canada (enrolling)
Health Clinical Research, LLC — Cutler Bay, Florida, United States (enrolling)
Northridge Clinical Trials — Northridge, California, United States (enrolling)
Revival Research Institute, LLC — Troy, Michigan, United States (enrolling)
Stracskin — Portsmouth, New Hampshire, United States (enrolling)
Center For Dermatology Clinical Research, Inc. — Fremont, California, United States (enrolling)
Royal London Hospital — London, United Kingdom
Chelsea and Westminster Hospital NHS Foundation Trust — London, United Kingdom
Salford Royal Hospital — Salford, United Kingdom
Brigham and Women's Hospital — Boston, Massachusetts, United States
Ryan Clinical Research Inc. — Newmarket, Canada
SIMa Recherche — Verdun, Canada
Beijing Friendship Hospital Affiliate of Capital University — Beijing, China
Huashan Hospital, Fudan University — Shanghai, China
Shanghai Skin Disease Hospital — Shanghai, China
Tianjin Medical University General Hospital — Tianjin, China
Erasmus Medisch Centrum — Rotterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.